Product: PCNA Antibody
Catalog: AF0239
Description: Rabbit polyclonal antibody to PCNA
Application: WB IHC IF/ICC
Cited expt.: WB, IHC, IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 36kDa; 29kD(Calculated).
Uniprot: P12004
RRID: AB_2833414

View similar products>>

   Size Price Inventory
 50ul $150 In stock
 100ul $250 In stock
 200ul $350 In stock
 1ml $1200 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC 1:100
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Zebrafish(88%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
PCNA antibody detects endogenous levels of total PCNA.
RRID:
AB_2833414
Cite Format: Affinity Biosciences Cat# AF0239, RRID:AB_2833414.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ATLD2; cb16; Cyclin; DNA polymerase delta auxiliary protein; etID36690.10; fa28e03; fb36g03; HGCN8729; MGC8367; Mutagen-sensitive 209 protein; OTTHUMP00000030189; OTTHUMP00000030190; PCNA; Pcna/cyclin; PCNA_HUMAN; PCNAR; Polymerase delta accessory protein; Proliferating cell nuclear antigen; wu:fa28e03; wu:fb36g03;

Immunogens

Immunogen:

A synthesized peptide derived from human PCNA.

Uniprot:
Gene(ID):
Description:
PCNA This protein is an auxiliary protein of DNA polymerase delta and is involved in the control of eukaryotic DNA replication by increasing the polymerase's processibility during elongation of the leading strand. Belongs to the PCNA family. Homotrimer. Forms a complex with activator 1 heteropentamer in the presence of ATP.
Sequence:
MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTYRCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMDLDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNIKLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLSMSADVPLVVEYKIADMGHLKYYLAPKIEDEEGS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Chicken
100
Rabbit
100
Zebrafish
88
Xenopus
63
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Auxiliary protein of DNA polymerase delta and is involved in the control of eukaryotic DNA replication by increasing the polymerase's processibility during elongation of the leading strand. Induces a robust stimulatory effect on the 3'-5' exonuclease and 3'-phosphodiesterase, but not apurinic-apyrimidinic (AP) endonuclease, APEX2 activities. Has to be loaded onto DNA in order to be able to stimulate APEX2. Plays a key role in DNA damage response (DDR) by being conveniently positioned at the replication fork to coordinate DNA replication with DNA repair and DNA damage tolerance pathways. Acts as a loading platform to recruit DDR proteins that allow completion of DNA replication after DNA damage and promote postreplication repair: Monoubiquitinated PCNA leads to recruitment of translesion (TLS) polymerases, while 'Lys-63'-linked polyubiquitination of PCNA is involved in error-free pathway and employs recombination mechanisms to synthesize across the lesion.

PTMs:

Phosphorylated. Phosphorylation at Tyr-211 by EGFR stabilizes chromatin-associated PCNA.

Acetylated by CREBBP and p300/EP300; preferentially acetylated by CREBBP on Lys-80, Lys-13 and Lys-14 and on Lys-77 by p300/EP300 upon loading on chromatin in response to UV irradiation. Lysine acetylation disrupts association with chromatin, hence promoting PCNA ubiquitination and proteasomal degradation in response to UV damage in a CREBBP- and EP300-dependent manner. Acetylation disrupts interaction with NUDT15 and promotes degradation.

Ubiquitinated. Following DNA damage, can be either monoubiquitinated to stimulate direct bypass of DNA lesions by specialized DNA polymerases or polyubiquitinated to promote recombination-dependent DNA synthesis across DNA lesions by template switching mechanisms. Following induction of replication stress, monoubiquitinated by the UBE2B-RAD18 complex on Lys-164, leading to recruit translesion (TLS) polymerases, which are able to synthesize across DNA lesions in a potentially error-prone manner. An error-free pathway also exists and requires non-canonical polyubiquitination on Lys-164 through 'Lys-63' linkage of ubiquitin moieties by the E2 complex UBE2N-UBE2V2 and the E3 ligases, HLTF, RNF8 and SHPRH. This error-free pathway, also known as template switching, employs recombination mechanisms to synthesize across the lesion, using as a template the undamaged, newly synthesized strand of the sister chromatid. Monoubiquitination at Lys-164 also takes place in undamaged proliferating cells, and is mediated by the DCX(DTL) complex, leading to enhance PCNA-dependent translesion DNA synthesis. Sumoylated during S phase.

Methylated on glutamate residues by ARMT1/C6orf211.

Subcellular Location:

Nucleus.
Note: Colocalizes with CREBBP, EP300 and POLD1 to sites of DNA damage (PubMed:24939902). Forms nuclear foci representing sites of ongoing DNA replication and vary in morphology and number during S phase. Together with APEX2, is redistributed in discrete nuclear foci in presence of oxidative DNA damaging agents.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Family&Domains:

Belongs to the PCNA family.

Research Fields

· Cellular Processes > Cell growth and death > Cell cycle.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Tight junction.   (View pathway)

· Genetic Information Processing > Replication and repair > DNA replication.

· Genetic Information Processing > Replication and repair > Base excision repair.

· Genetic Information Processing > Replication and repair > Nucleotide excision repair.

· Genetic Information Processing > Replication and repair > Mismatch repair.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

References

1). A novel UV-curable extravascular stent to prevent restenosis of venous grafts. Composites Part B: Engineering, 2021 [IF=12.7]

Application: WB    Species: Rat    Sample:

Fig. 6. A: PCNA immunofluorescence staining of venous graft vessels in rats. B, C: Western blot analysis of α-SMA, PCNA, ICAM-1, VCAM-1, and vimentin in rat vein graft vessels. D: ICAM-1 immunofluorescence staining of venous graft vessels in rats. E: qPCR of α-SMA, PCNA, ICAM-1, VCAM-1, and vimentin in rat vein graft vessels. Data are presented as the mean ± SD; *: compared with control group, p < 0.05. #: compared with sham group,

Application: IF/ICC    Species: Rat    Sample:

Fig. 6. A: PCNA immunofluorescence staining of venous graft vessels in rats. B, C: Western blot analysis of α-SMA, PCNA, ICAM-1, VCAM-1, and vimentin in rat vein graft vessels. D: ICAM-1 immunofluorescence staining of venous graft vessels in rats. E: qPCR of α-SMA, PCNA, ICAM-1, VCAM-1, and vimentin in rat vein graft vessels. Data are presented as the mean ± SD; *: compared with control group, p < 0.05. #: compared with sham group, p < 0.05.

2). NLRP3 inflammasome constrains liver regeneration through impairing MerTK-mediated macrophage efferocytosis. Science Advances, 2025 [IF=11.7]

3). NLRP3 inflammasome constrains liver regeneration through impairing MerTK-mediated macrophage efferocytosis. Science Advances, 2025 [IF=11.7]

4). Graphene foam/hydrogel scaffolds for regeneration of peripheral nerve using ADSCs in a diabetic mouse model. Nano Research, 2021 [IF=9.5]

5). Quercetin inhibited mesangial cell proliferation of early diabetic nephropathy through the Hippo pathway. PHARMACOLOGICAL RESEARCH, 2019 (PubMed: 31220559) [IF=9.1]

Application: IF/ICC    Species: mouse    Sample: glomerular mesangial cells

Fig.1.|Treatment with quercetin ameliorated the proliferation of high glucose-cultured glomerular mesangial cells. (A and B)Distribution and expression of PCNA and ki67 through immunofluorescence.

Application: IHC    Species: mouse    Sample: renal cortex

Fig. 5.| Quercetin ameliorated the glomerular mesangial cell proliferation of diabetic mice. (A) Renal ultra-structural changes of diabetic mice by transmission electron microscope. (B) Glomerular mesangial cell proliferation activity detected by 5-ethynyl-20-deoxyuridine incorporation assay. Scale bar = 20 μm. (C)Distribution and expression of ki67 and PCNA in renal cortex of diabetic mice through immunohistochemistry. Scale bar = 20 μm. 4.

6). Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine. International Journal of Biological Sciences, 2023 (PubMed: 37151876) [IF=8.2]

Application: WB    Species: Human    Sample: HCT 8 cells and HCT 116 cells

Figure 5 The BBR-associated differential metabolite LPC contributes to cell proliferation and cell junction impairment. (A) Cell growth curves of the CRC cell lines HCT116, HCT-8, SW480, and the normal intestinal epithelial cell line IEC-6, with or without LPC treatment. (B) HCT 116 cells and HCT 8 cells with or without LPC treatment were analyzed with flow cytometry. (C) Expression of β-catenin and PCNA in HCT 8 cells and HCT 116 cells with or without LPC treatment. (D) Expression of IL-6 and p-STAT3 in Raw 264.7 cells with or without LPC treatment. (E) Expression of occludin and E-cadherin in HCT-8 cells and HCT-116 cells co-cultured with Raw264.7 cells with or without LPC treatment.

7). ASIC1a promotes hepatic stellate cell activation through the exosomal miR-301a-3p/BTG1 pathway. International Journal of Biological Macromolecules, 2022 (PubMed: 35561854) [IF=7.7]

8). Human umbilical cord-derived mesenchymal stem cells improve the function of liver in rats with acute-on-chronic liver failure via downregulating Notch and Stat1/Stat3 signaling. Stem Cell Research & Therapy, 2021 (PubMed: 34256837) [IF=7.5]

Application: IHC    Species: Rat    Sample: liver tissue

Fig. 7 The effects of hUC-MSC transplantation on hepatocyte regeneration in ACLF rats. Liver sections from ACLF rats 12 and 24 h post-hUC-MSC transplantation or 0.9% sodium chloride injection as a control were used for immunohistochemical staining of AFP, CK18, HGF, and PCNA and microscopic examination (n = 4/group). Representative photographs are shown (a). Positive staining was quantified and is presented as the mean ± SD (b, c). d Serum levels of HGF were detected by ELISA (4h, n = 3/group; 12h and 24h, n = 4/group). Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001

9). Caffeic acid mitigates myocardial fibrosis and improves heart function in post-myocardial infarction by inhibiting transforming growth factor-β receptor 1 signaling pathways. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024 (PubMed: 38906025) [IF=6.9]

10). YY1/HIF-1α/mROS positive-feedback loop exacerbates glomerular mesangial cell proliferation in mouse early diabetic kidney disease. Acta pharmacologica Sinica, 2025 (PubMed: 40038466) [IF=6.9]

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.